1 Larkin BA, Copeland JRM, Dewey ME, Davidson IA, Saunders PA.
The natural history of neurotic disorders in an elderly urban population: Findings from the Liverpool Longitudinal Study of Continuing Health in the Community.
Br J Psychiatry 1992;160:681-6.

2 Manela M, Katona C, Livingston G.
How common are the anxiety disorders in old age?
Intern J Geriatr Psychiatry 1996;11:65-70.

3 American Psychiatric Association.
Diagnostic and Statistical Manual of Mental Disorders.
4th ed. Washington, DC: American Psychiatric Association 1994.

4 Salzman C, Sheikh JI.
Diagnosis of anxiety and anxiety-related disorders.
In: Salzman C, ed. Clinical Geriatric Psychopharmacology. Baltimore: William & Wilkins 1998:333-42.

5 Krasucki C, Howard R, Mann A.
Anxiety and its treatment in the elderly.
Intern Psychogeriatrics 1999;11:25-45.

6 Vita A.
Cause organiche di ansia nell'anziano.
In: Gribomont B, ed. Ansia e disturbi del sonno in età avanzata. London: Royal Society of Medicine Press Ltd 1998:11-18.

7 Salzman C.
Treatment of anxiety and anxiety-related disorders.
In: Salzman C, ed. Clinical Geriatric Psychopharmacology. Baltimore: William & Wilkins 1998;343-68.

8 Vampini C.
Principi per un impiego razionale degli antidepressivi negli anziani.
Roma: Casa Editrice Scientifica Internazionale 1997.

9 Bellantuono C, Rizzo R, Balestrieri M.
Psicofarmacoterapia delle sindromi ansiose.
In: Bellantuono C, Balestrieri M, eds. Gli Psicofarmaci. Farmacologia e Terapia. Roma: Il Pensiero Scientifico Editore 1997a:215-98.

10 Balter MB, Manheimer DI, Mellinger GD, Uhlenhuth EH.
A cross national comparison of anti-anxiety/sedative drug use.
Curr Med Res Op 1984;8(suppl.4):5-20.

11 Balestrieri M, Bortolomasi M, Galletta M, Bellantuono C.
Patterns of hypnotic drug prescription in Italy. A two-week community survey.
Br J Psychiatry 1997;170:176-80.

12 Kirby M, Denihan A, Bruce I, Radic A, Coakley D, Lawlor BA.
Benzodiazepine use among the elderly in the community.
Intern J Geriatr Psychiatry 1999;14:280-4.

13 Sethy VH, Hodges DH.
Role of a-adrenergic receptors in the antidepressant effects of alprazolam.
Res Comm Chem Pathol Pharmacol 1982;36:2329-32.

14 Koerncki E, Lenox RH, Hardwick DH, et al.
Interactions of the alkyl-ether-phospholipid, platelet activating factor (PAF) with platelets, neural cells, and the psychotropic drugs triazolobenzodiazepines.
Adv Exp Med Biol 1987;221:447-88.

15 Broderick PA.
Alprazolam, diazepam, yohimbine, clonidine: in vivo CA1 hippocampal norepinephrine and serotonin release profiles under chloral hydrate anesthesia.
Progress in Neuro-Psychopharmacology & Biological Psychiatry 1997;21:1117-40.

16 Torta R, Borio R, Cicolin A.
La terapia ansiolitica nel paziente anziano: aspetti clinico farmacologici.
Milano: Excerpta Medica, Reed Elsevier Group 1994.

17 Bellantuono C, Vampini C, Balestrieri M.
Psicofarmacoterapia delle sindromi depressive.
In: Bellantuono C, Balestrieri M, eds. Gli Psicofarmaci. Farmacologia e Terapia. Roma: Il Pensiero Scientifico Editore 1997b:215-98.

18 Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, Shader RI.
Alprazolam kinetics in the elderly.
Arch Gen Psychiatry 1983;40:287-90.

19 Herings RMC, Stricker BHC, de Boer A, et al.
Benzodiazepines and the risk of falling leading to femur fractures.
Arch Int Med 1995;155:1801-7.

20 Hemmelgarn B, Suissa S, Huang A.
Benzodiazepine use and the risk of motor vehicle crash in the elderly.
JAMA 1997;278:27-31.

21 Foy A, O' Connel, Henry D, et al.
Benzodiazepine use as a cause of cognitive impairment in elderly hospital inpatients.
J Gerontol 1995;50A:M99-106.

22 Rummans TA, Davis LJ, Morese RM, et al.
Learning and memory impairment in older, detoxified, benzodiazepine-dependent patients.
Mayo Clinic Proceedings 1993;68:731-7.

23 Roy-Byrne P, Fleishhacker J, Arnett C, et al.
Effects on acute and chronic alprazolam treatment on cerebral blood flow, memory, sedation, and plasma cathecolamines.
Neuropsychopharmacology 1993;8:161-9.

24 Cohn JB.
Double-blind safety and efficacy comparison of alprazolam and placebo in the treatment of anxiety in geriatric patients.
Curr Ther Res 1984;35:100-12.

25 Bellantuono C.
Rischi e benefici del trattamento a lungo termine con benzodiazepine.
Bollettino di Aggiornamento in Neuropsicofarmacologia 1998;XIV:1-3.

26 Smith S, Sherill KA, Colenda CC.
Assessing and treating anxiety in elderly persons.
Psychiatric Services 1995;46:36-42.

27 Napoliello MJ.
An interim multicentre report on 667 anxious geriatric out-patients treated with buspirone.
Br J Clin Pract 1986;40:71-3.

28 Hart RP, Colenda CC, Hamer RM.
Effects of buspirone and alprazolam on the cognitive performance of normal elderly subjects.
Am J Psychiatry 1991;148:73-7.

29 Barbee JG, McLaulin JB.
Anxiety disorders: Diagnosis and pharmacotherapy in the elderly.
Psychiatr Ann 1990;20:439-45.

30 Balestrieri M, Ruggeri M, Bellantuono C.
Drug treatament of panic disorder. A critical review of controlled clinical trials.
Psychiatr Develop 1989;4:337-50.

31 Javaid I, Sheikh MD, Pamela J, Swales PHD.
Treatment of panic disorders in older adults: a pilot study comparison of alprazolam, imipramine, and placebo.
Intern J Psich Med 1999;29:107-17.

32 Wilkinson G, Balestrieri M, Ruggeri M, Bellantuono C.
Meta-analysis of double-blind placebo-controlled trials of antidepressants and benzodiazepines for patients with panic disorders.
Psychol Med 1991;21:991-8.

33 Bellantuono C, Vampini C, Balestrieri M.
I nuovi antipsicotici. Efficacia, tollerabilità e modalità d'uso nella pratica clinica.
Roma: Il Pensiero Scientifico Editore 1999.

34 Tariot PN.
Treatment strategies for agitation and psychosis in dementia.
J Clin Psychiatry 1996;57(suppl.14):21-9.

35 Zayas EM, Grossberg GT.
Treating the agitated Alzheimer patient.
J Clin Psychiatry 1996;57(suppl.7):46-51.